“Build It And They Will Come” – North Star Holdings Unveils Cannabis Research Initiatives

© Provided by Benzinga The United States is falling behind the global stage in cannabis research. The United Kingdom, the European Union, Canada and Israel are well in advance with companies spawned such as GW Pharmaceuticals that already have an FDA approved therapeutic using cultivated cannabis as its source.

The company recently announced it submitted seven research license applications to the Drug Enforcement Administration (DEA) with intentions to nationally offer cannabis and cannabis derived extracts for those looking to create novel therapeutics. John Kaweske, North Star’s CEO and Founder, strongly believes in the potential of cannabis and its benefits saying “It is not a coincidence that both nature and the human body have a cannabinoid system.” 

A Head Start

The DEA is no longer considering new applications for cannabis research, causing those who applied prior to January 19, 2021 to gain a preferential status with the DEA for approval. Some estimate that this gives North Star and the early applicants an 18 month to 24 month advantage over competitors.

North Star is well positioned to be a leader in cannabis flower and extracts for research at universities, pharmaceutical and biotechnology institutions. With 140 acres of outdoor cultivation over 500,000 square feet of indoor and greenhouse cultivation and now is the only company with multiple licenses pending with the DEA.  

Offering Quality and Variety

With over 300 strains in its library of cannabis plant genetics, North Star cultivates approximately 120 genetic variations across all of its locations to offer an array of options to the medical sector of the industry. The company aims to use its high quality cannabis variations to work primarily with universities, pharmaceutical and biotech companies in research development. 

“We intend to offer researchers numerous cannabis genetic varieties to choose from in order to conduct research,” Mr. Kaweske stated in a press release in early February 2021. “Cannabis research may unlock new drug development for future FDA and EMA approved treatments.”

North Star’s motives have been simple and unwavering since its inception in 2015. “We got into this business to help make people’s lives better,” Kaweske states. “And that’s our primary goal, to make the world a better place.” 

North Star is committed to pharmaceutical grade production of cannabis and cannabis extracts in addition to its thriving core retail, manufacturing and cultivation businesses in Colorado, Las Vegas Nevada, Utah, and California under the brands such as Tweedleaf™, XLeaf™, Leaflabs™, Cannadews™, Ascended Lab’s™, Camino Real™ and Carolina’s Medicinals™.

For more information visit https://www.northstarholdings.com/.

Photo by Kimzy Nanney

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.